Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome

Abstract

The addition of apixaban, at a dose of 5 mg twice daily, to antiplatelet therapy in high-risk patients after an acute coronary syndrome increased the number of major bleeding events without a significant reduction in recurrent ischemic events. (Funded by Bristol-Myers Squibb and Pfizer; APPRAISE-2 ClinicalTrials.gov number, NCT00831441.).

Keywords

Acute coronary syndromeApixabanMedicineCardiologyInternal medicineTicagrelorClopidogrelIntensive care medicineAspirinMyocardial infarctionRivaroxabanAtrial fibrillationWarfarin

Affiliated Institutions

Related Publications

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi , Steven O’Day , David F. McDermott +26 more

Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. Adverse eve...

2010 New England Journal of Medicine 14794 citations

Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

R B Sleight , Peter Sleight , Sarah Parish +3 more

17,187 patients entering 417 hospitals up to 24 hours (median 5 hours) after the onset of suspected acute myocardial infarction were randomised, with placebo control, between: (...

1988 PubMed 2873 citations

2023 ESC Guidelines for the management of acute coronary syndromes

Robert A. Byrne , Xavier Rosselló , J J Coughlan +97 more

peer reviewed

2023 European Heart Journal 3370 citations

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

James Larkin , Vanna Chiarion‐Sileni , René González +28 more

BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advance...

2019 New England Journal of Medicine 3500 citations

Publication Info

Year: 2011
Type: article
Volume: 365
Issue: 8
Pages: 699-708
Citations: 990
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

990

OpenAlex

Cite This

APA Style

                            
                                
                                    John H. Alexander, 
                                
                                    Renato D. Lópes, 
                                
                                    Stefan James
                                
                                et al.
                            
                            (2011). 
                            Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. 
                            New England Journal of Medicine
                            , 365
                            (8)
                            , 699-708.
                            https://doi.org/10.1056/nejmoa1105819
                        

Identifiers

DOI: 10.1056/nejmoa1105819